TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34713614

Group type: EXPERIMENTAL
Intervention: 3MC (ART provided three-monthly in community ART groups)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: 6MC (ART provided six-monthly in either CAGs or at community-distribution points)
Number of subjects: 599

Group type: COMPARATOR
Intervention: SoC (Standard-of-care three-monthly ART provision at healthcare facilities)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: 3MC
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: 6MC
Number of subjects: 599
Study: 34713711

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification program
Number of subjects: 0
Study: 34713738

Group type: EXPERIMENTAL
Intervention: Nondirected uterus donation
Number of subjects: 44
Study: 34713745

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination
Number of subjects: 88
Study: 34713782

Group type: EXPERIMENTAL
Intervention: Statin treatment in patients with ischemic heart disease (IHD)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Long-acting insulins in patients with type 1 DM
Number of subjects: 5808

Group type: COMPARATOR
Intervention: Spironolactone treatment in patients with CHF
Number of subjects: 5808

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD)
Number of subjects: 5808
Study: 34713932

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 30
Study: 34714159

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34714423

Group type: EXPERIMENTAL
Intervention: Elevated pretreatment CEA
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Elevated pretreatment CA 19-9
Number of subjects: 788

Group type: COMPARATOR
Intervention: Patients without elevated tumor markers
Number of subjects: 788

Group type: COMPARATOR
Intervention: Patients with either elevated CEA or CA 19-9
Number of subjects: 788

Group type: COMPARATOR
Intervention: Patients with both elevated CEA and CA 19-9
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Preoperative presence of ctDNA
Number of subjects: 788
Study: 34714450

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) combined with radiation therapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) combined with cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ICI with RT and cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized phase II studies (P-RAD and ipilimumab/nivolumab/cryoablation)
Number of subjects: 0
Study: 34714527

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly
Number of subjects: 2677
Study: 34714555

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM/DEX)
Number of subjects: 151
Study: 34714558

Group type: EXPERIMENTAL
Intervention: Prognostic radiomics score (RS) derived from PET radiomics features
Number of subjects: 133
Study: 34714708

Group type: EXPERIMENTAL
Intervention: Craniospinal RT dose of 23.4 Gy for average-risk patients and 36-39.6 Gy for high-risk patients, boost dose of 55.8 Gy to the tumor bed.
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Increasing RT dose to the corpus callosum (CC) or frontal white matter (WM) and hippocampus.
Number of subjects: 124
Study: 34714976

Group type: COMPARATOR
Intervention: PROPEL usual care
Number of subjects: 2210

Group type: EXPERIMENTAL
Intervention: REPOWER in-clinic individual visits
Number of subjects: 2210

Group type: EXPERIMENTAL
Intervention: REPOWER telephone group visits
Number of subjects: 2210

Group type: EXPERIMENTAL
Intervention: REPOWER in-clinic group visits
Number of subjects: 2210

Group type: EXPERIMENTAL
Intervention: PROPEL in-clinic and telephone visits
Number of subjects: 2210
Study: 34715884

Group type: EXPERIMENTAL
Intervention: Platelet soluble (s)CD40L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet soluble (s)CD62P
Number of subjects: 0
Study: 34715906

Group type: EXPERIMENTAL
Intervention: Organizational Skills Training (OST)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 142
Study: 34716161

Group type: EXPERIMENTAL
Intervention: Modified downregulation with GnRH analogue for 6 weeks
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard downregulation with GnRH analogue for 1 week
Number of subjects: 162
Study: 34716177

Group type: EXPERIMENTAL
Intervention: Adavosertib 300 mg daily on days 1 through 5 and 8 through 12 of a 21-day cycle
Number of subjects: 120
Study: 34716196

Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 91
Study: 34716198

Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg i.v. every 6 weeks) plus Nivolumab (240 mg i.v. every 2 weeks)
Number of subjects: 17
Study: 34716199

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 70
Study: 34716216

Group type: EXPERIMENTAL
Intervention: Somatic alterations in PKD1 or PKD2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Short mutations in PKD1 or PKD2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Somatic chromosomal loss of heterozygosity (LOH) events
Number of subjects: 24
Study: 34716565

Group type: COMPARATOR
Intervention: Oral BI 425809 25 mg (single dose) on day 1; multiple doses of itraconazole or rifampicin combined with a single dose of oral BI 425809 25 mg on day 4/7.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral BI 425809 25 mg (single dose) on day 1; multiple doses of rifampicin combined with a single dose of oral BI 425809 25 mg on day 4/7.
Number of subjects: 0
Study: 34716570

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 808

Group type: COMPARATOR
Intervention: Non-AF patients
Number of subjects: 808
Study: 34716759

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OR-1896 (active metabolite of Levosimendan)
Number of subjects: 0
Study: 34716790

Group type: EXPERIMENTAL
Intervention: Hemp meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buckwheat meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Meat meal (beef)
Number of subjects: 10
Study: 34716838

Group type: EXPERIMENTAL
Intervention: Synchronous pathway
Number of subjects: 125

Group type: COMPARATOR
Intervention: Staged pathway
Number of subjects: 125

Group type: COMPARATOR
Intervention: Staged surgery
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Synchronous surgery
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: All surgical groups
Number of subjects: 125
Study: 34716965

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided conventional radiofrequency (RF) treatment of the genicular nerves
Number of subjects: 59
Study: 34717057

Group type: EXPERIMENTAL
Intervention: Serum anti-Müllerian hormone (AMH) levels measured using the Elecsys AMH Plus immunoassay
Number of subjects: 47
Study: 34717097

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 178
Study: 34717300

Group type: EXPERIMENTAL
Intervention: BMI classification (underweight, normal, overweight)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: FIM gain
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: BMI change from admission to discharge
Number of subjects: 247
Study: 34717553

Group type: EXPERIMENTAL
Intervention: Germline DNA self-sampling using saliva sampling kits sent by postal mail
Number of subjects: 928

Group type: COMPARATOR
Intervention: Written reminders
Number of subjects: 928

Group type: COMPARATOR
Intervention: Demographic and clinical factors
Number of subjects: 928
Study: 34717578

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMO)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'FL)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy BMI
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Children of non-secretors
Number of subjects: 143
Study: 34717585

Group type: EXPERIMENTAL
Intervention: Bolus-tracking II (BT II)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Bolus-tracking I (BT I)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Test bolus II (TB II)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Test bolus I (TB I)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Traditional groups
Number of subjects: 141

Group type: COMPARATOR
Intervention: Traditional aorta scan group
Number of subjects: 141
Study: 34717606

Group type: EXPERIMENTAL
Intervention: IFAB questionnaire (10-item)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IPAQ-S questionnaire
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Stages of behaviour change
Number of subjects: 150

Group type: COMPARATOR
Intervention: Steps per day (collected by smartphone)
Number of subjects: 150
Study: 34717608

Group type: EXPERIMENTAL
Intervention: Non-ablative radiofrequency (RF) treatment (41°C) for five sessions with one week intervals
Number of subjects: 11
Study: 34717616

Group type: EXPERIMENTAL
Intervention: EHR-based insurance support tool
Number of subjects: 46
Study: 34717627

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 4212

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4212

Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 4212
Study: 34717717

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus chemoradiotherapy (experimental group)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone (control group)
Number of subjects: 378
Study: 34717726

Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty (ESG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 30
Study: 34717736

Group type: EXPERIMENTAL
Intervention: Bridge clinic referral
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 34717797

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (≤5 fractions with ≥7 Gy per fraction) or hypofractionated intensity-modulated radiotherapy (60-70 Gy in ten fractions or 52.5-67.5 Gy in 15 fractions) to all lesions.
Number of subjects: 30
Study: 34717922

Group type: EXPERIMENTAL
Intervention: miR-338-5p expression
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cigarette smoking history
Number of subjects: 43
Study: 34718191

Group type: EXPERIMENTAL
Intervention: Severe TBI individuals
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Severe TBI individuals with GOSE 3-5
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Baseline DTI imaging
Number of subjects: 22
Study: 34718447

Group type: EXPERIMENTAL
Intervention: Oral treprostinil for 1 year
Number of subjects: 12
Study: 34718493

Group type: EXPERIMENTAL
Intervention: Warfarin (INR: 2-2.5) and Aspirin (withheld after first bleeding episode)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Post-implant vWf:Ag and vWf:CB
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pathological vWf:CB/vWf:Ag ratio (<0.7)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: vWf:CB in bleeders vs non-bleeders at t2
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: vWf:CB/vWf:Ag ratio in bleeders vs non-bleeders at t2
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Aspirin discontinuation
Number of subjects: 53
Study: 34718501

Group type: EXPERIMENTAL
Intervention: Surgical treatment for post-infarction PMR with mitral valve replacement and concomitant coronary artery bypass grafting (CABG) in 57% of cases.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Surgical treatment for post-infarction PMR.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Surgical treatment for post-infarction PMR with concomitant CABG.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Preoperative chronic kidney dysfunction, cardiac arrest, and cardiopulmonary bypass duration as risk factors.
Number of subjects: 214
Study: 34718510

Group type: EXPERIMENTAL
Intervention: Transfontanellar contrast-enhanced ultrasound (T-CEUS) during REEEA
Number of subjects: 9
Study: 34718636

Group type: EXPERIMENTAL
Intervention: Higher antibodies to Ae. aegypti salivary proteins
Number of subjects: 771
Study: 34718665

Group type: EXPERIMENTAL
Intervention: Serum bile acid (sBA) profiles measured by tandem MS at ages 3-6 and 9 months
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Serum glycocholic acid (GCA)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Proportion of GCA
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Bile acid composition
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Restoration of intestinal BA homeostasis
Number of subjects: 365

Group type: COMPARATOR
Intervention: Well-nourished local children
Number of subjects: 365
Study: 34718764

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 213
Study: 34718774

Group type: EXPERIMENTAL
Intervention: [18F]FDG PET
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 14

Group type: COMPARATOR
Intervention: [18F]FDG uptake
Number of subjects: 14
Study: 34718859

Group type: EXPERIMENTAL
Intervention: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks) in FADS1 rs174550-CC genotype
Number of subjects: 59
Study: 34718884

Group type: EXPERIMENTAL
Intervention: NOAC (non-vitamin K-dependent oral antagonists)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: In-hospital treatment after stroke
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Rivaroxaban or apixaban
Number of subjects: 1080
Study: 34719115

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 0
Study: 34719198

Group type: EXPERIMENTAL
Intervention: Repeated intrathecal injections of autologous mesenchymal stem cells, dosage and duration not available
Number of subjects: 0
Study: 34719715

Group type: EXPERIMENTAL
Intervention: Tracheal pepsin A measurement
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (no tracheal pepsin A measurement)
Number of subjects: 297
Study: 34721255

Group type: EXPERIMENTAL
Intervention: 60 Min Electrostimulation with the EXOPULSE Mollii Suit
Number of subjects: 0
Study: 34721403

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 68
Study: 34721420

Group type: EXPERIMENTAL
Intervention: anti-CD25 induction
Number of subjects: 117

Group type: COMPARATOR
Intervention: TCMR
Number of subjects: 117
Study: 34722242

Group type: EXPERIMENTAL
Intervention: AGIG chemo-immunotherapy regimen (nab-paclitaxel + gemcitabine + IL-2 + GM-CSF)
Number of subjects: 64
Study: 34722269

Group type: EXPERIMENTAL
Intervention: Regionally administered melphalan
Number of subjects: 2
Study: 34722275

Group type: EXPERIMENTAL
Intervention: Upfront RT
Number of subjects: 198

Group type: COMPARATOR
Intervention: Deferred RT
Number of subjects: 198
Study: 34722563

Group type: EXPERIMENTAL
Intervention: MMGA (multimodal general anesthesia) using intravenous remifentanil, ketamine, dexmedetomidine, magnesium, and bupivacaine as a pecto-intercostal fascial block.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MMGA (multimodal general anesthesia)
Number of subjects: 20
Study: 34722661

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory medications, specific type and dosage not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific treatment not available
Number of subjects: 0
Study: 34722667

Group type: EXPERIMENTAL
Intervention: Angiography-Derived IMR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34722810

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes, 6750 cGyRBE for prostate and 4500 cGyRBE for pelvic lymph nodes in 25 daily fractions, all received androgen-deprivation therapy.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Presence of baseline GU symptoms
Number of subjects: 56
Study: 34723054

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1262
Study: 34723634

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34723820

Group type: EXPERIMENTAL
Intervention: DOZE app (self-management intervention)
Number of subjects: 83
Study: 34723822

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Public-facing campaign addressing mental health stigma
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Service-level adjustments for staff
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Establishment of a suitable clinical training curriculum for health care professionals
Number of subjects: 69
Study: 34723826

Group type: EXPERIMENTAL
Intervention: Workplace-based HIV self-testing using OraQuick test kits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine HTS at work premises
Number of subjects: 0
Study: 34723824

Group type: EXPERIMENTAL
Intervention: FITxOlder (Community Health Worker-led Chinese Qigong mind-body exercise program)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: FITxOlder
Number of subjects: 49
Study: 34723858

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0
Study: 34724112

Group type: EXPERIMENTAL
Intervention: Optogenetic treatment (irreversible gene therapy) with specially designed goggles for light delivery
Number of subjects: 0
Study: 34724115

Group type: EXPERIMENTAL
Intervention: 4SCAR-GD2 T-cell treatment
Number of subjects: 10
Study: 34724226

Group type: EXPERIMENTAL
Intervention: Molibresib 75 mg once daily
Number of subjects: 0
Study: 34724240

Group type: EXPERIMENTAL
Intervention: Intravenous arginine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34724453

Group type: EXPERIMENTAL
Intervention: Daily step counts measured using armband accelerometers worn for 7 days, with a median of 1170 steps daily.
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Daily step counts measured using armband accelerometers worn for 7 days.
Number of subjects: 531
Study: 34724566

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Loss of HLA-B*40:02
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: HLA-B*07:02 and HLA-B*40:01 genotypes and their loss
Number of subjects: 544
Study: 34724624

Group type: EXPERIMENTAL
Intervention: Laboratory confirmed dengue (LCD)
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Non-LCD
Number of subjects: 2004
Study: 34724906

Group type: EXPERIMENTAL
Intervention: Responses from participants regarding their HDP experience
Number of subjects: 3202
Study: 34725072

Group type: EXPERIMENTAL
Intervention: IV DEXA (24 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 34725077

Group type: EXPERIMENTAL
Intervention: In-bed leg cycling for 30 minutes daily for 14 consecutive days, initiated within 48 hours of spinal surgery.
Number of subjects: 45

Group type: COMPARATOR
Intervention: In-bed leg cycling
Number of subjects: 45
Study: 34725108

Group type: EXPERIMENTAL
Intervention: mTOR inhibitors (mTORis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA)
Number of subjects: 0
Study: 34725214

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (SCRT) followed by CAPOX (capecitabine and oxaliplatin) and camrelizumab
Number of subjects: 30
Study: 34725215

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34725289

Group type: EXPERIMENTAL
Intervention: Tregocel® nutraceutical supplement
Number of subjects: 107
Study: 34725726

Group type: EXPERIMENTAL
Intervention: Needles with prostate cancer (PCa)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Needles without prostate cancer (PCa)
Number of subjects: 5
Study: 34726532

Group type: EXPERIMENTAL
Intervention: Symmetric collateral pattern at CT angiography (CTA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Malignant collateral pattern at CT angiography (CTA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Other collateral pattern at CT angiography (CTA)
Number of subjects: 31
Study: 34726579

Group type: EXPERIMENTAL
Intervention: PROMIS® short forms
Number of subjects: 884
Study: 34726607

Group type: EXPERIMENTAL
Intervention: Participant-centric digital health study approach with high friction app-based assessments and wearable sensors.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Participant engagement strategy with regular phone check-ins.
Number of subjects: 365
Study: 34726610

Group type: EXPERIMENTAL
Intervention: Peer-delivered eHealth intervention (3 sessions delivered weekly over 3 weeks)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 620
Study: 34726763

Group type: EXPERIMENTAL
Intervention: SQoL-6D Total score change
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Global Assessment of Benefit scale
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: GASeous tool
Number of subjects: 104
Study: 34726887

Group type: EXPERIMENTAL
Intervention: SY-5609, a selective, noncovalent inhibitor of CDK7
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34727366

Group type: EXPERIMENTAL
Intervention: HS-10234 25 mg daily for 7 days (D1-D7) followed by emtricitabine 200 mg QD for 7 days (D8-D14)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Emtricitabine 200 mg QD for 7 days (D1-D7) followed by HS-10234 25 mg QD for 7 days (D8-D14)
Number of subjects: 36